AI vs. Human Diagnosis: Is LightAI Changing the Game?

This is sponsored content. Barchart is not endorsing the websites or products set forth below.

This article was disseminated on behalf of Light AI Inc. (CBOE: ALGO; OTCQB: OHCFF; FSE: 0HC)

Ever wished you could skip the doctor’s office and just use your phone to figure out what’s wrong? Well, AI in healthcare is making that dream closer to reality! But can AI really outdo human doctors when it comes to diagnosing illnesses? Or is it just a handy sidekick that helps make healthcare more accessible? Let’s break it down in a way that’s easy to understand—and maybe even a little fun!

AI Symptom Checkers: A Quick Fix or the Future

AI-powered symptom checkers, like LightAI, are changing how people approach healthcare. They offer quick assessments, guiding users toward the next steps for treatment. In low-income countries, access to doctors is often limited. AI-powered telehealth services are making a difference here. AI apps also assist with managing chronic diseases like diabetes, hypertension, and depression. Still, high-quality apps for rheumatoid arthritis and chronic pain are rare.

AI vs. Human Doctors: How Do They Compare?

Let’s look at how AI stacks up against traditional diagnosis:

• Accuracy: AI can diagnose diseases at a level comparable to human doctors. A Lancet Digital Study report on “human versus machine in medicine” showed that some AI models have outperformed human diagnosis. Deep learning algorithms had an accuracy rate of 87% while human analysis scored 86% in medical imaging analysis.
• Triage & Safety: AI tools like the Babylon Triage and Diagnostic System provide safe and accurate medical advice. They can be even more cautious than doctors at times.
• Doctors Want Control: The American Medical Association (AMA) found that doctors prefer AI tools that fit into their existing workflows, rather than completely changing how they practice medicine.

Sources: Pneumonia, Breast Cancer, Prostate Cancer

AI Integration in Rare Diseases

When it comes to rare diseases, AI can be many times better than a human doctor. That’s because AI has access to a much bigger database than a person could ever search through. 

For instance, an analysis from Nature.com revealed that advanced deep learning models like DenseNet121 have recorded up to 99.95% accuracy in breast cancer detection. That’s nearly flawless.

Doctors across many disciplines have already integrated AI into their work, including…

• Cancer
• Heart disease
• Alzheimer’s
• Skin conditions
• Glaucoma
• Lung diseases

Here’s a quick comparative snapshot of AI vs human analysis

AI in Healthcare: Faster, Smarter, and More Accurate

AI is changing how medicines are developed and how people check their health. The US leads in AI adoption in the pharmaceutical industry. China, the UK, Canada, and South Korea also play important roles.

In 2020, Japan’s Sumitomo Dainippon Pharma and the UK’s Exscientia developed the drug DSP-1181 using the latter’s AI platform for the treatment of obsessive-compulsive disorder (OCD). They completed the exploratory research phase in less than 12 months—a process that usually takes five years. This breakthrough shows how AI can revolutionize medicine by making treatments available much faster.

AI is also helping patients make better health decisions. Many people search their symptoms online, but this often leads to misleading or scary diagnoses. That’s why doctors discourage self-diagnosing through Google. 

However, with AI tools like ChatGPT, even experienced doctors have noticed patients arriving with surprisingly accurate self-assessments. Benjamin Tolchin, a Yale neurologist, who once criticized online symptom-checking, admitted that some of his patients’ AI findings were close to his own professional evaluations.

Meet LightAI: The AI That Checks Your Throat

One of the most exciting innovations in AI healthcare is LightAI (CBOE: ALGO; OTCQB: OHCFF; FSE: 0HC). This small but mighty AI company has developed software that can be used right from your phone. Imagine checking for strep throat at home—no doctor, no wooden paddle, and no lab tests!

Peter Whitehead, the founder and CEO of Light AI, has a strong background in the medical field. He invented VELScope, a tool for detecting oral cancer that is now used in over 10,000 dental practices across 23 countries. His success with VELScope proves he knows how to bring a medical device to the global stage.

With 24 years of experience in healthcare, Peter leads Light AI with deep industry knowledge. He is also backed by a team of medical veterans and AI experts, combining the best of both fields to create cutting-edge healthcare technology.

So, here’s how it works: 

You open the app, follow a few simple steps, and snap a photo of the patient’s throat. Within seconds, the AI analyzes the image, providing a finding.

Getting Smarter with Every Scan

Light AI is developing a tool that doesn’t just rely on what users describe. Instead, it analyzes throat images and compares them to over 300,000 past cases. This makes it far more accurate than traditional symptom checkers. By focusing on visible signs rather than just words, Light AI brings users closer to having a personal doctor at home.

While Light AI isn’t available for private use yet, it’s only a matter of time before it reaches the market. The company has already planned three paths to commercial launch, bringing AI-powered healthcare closer to everyday use.

AI needs to learn from existing data to improve over time. The more data it processes, the better it gets. Light AI has a big head start, with years of training and a huge amount of data, putting it ahead of future competitors.

• Its Strep A detection software has already analyzed over 300,000 throat images. With each image, its accuracy has improved.
• Right now, pre-FDA studies show that Light AI can rule out bacterial infections with an impressive 97% accuracy.

Any company trying to compete will need to spend time and money to train their AI. Without this training, their product will always be less effective—giving Light AI a strong edge in the market.

But Light AI isn’t stopping here. It aims to keep enhancing its software by adding more diseases. This will make AI-powered healthcare even more dependable.

Quick Check: What Makes This So Unique

• Highly Accurate –The algorithm reached over 96% accuracy, with a 97% success rate matching the "Gold Standard" swab test for diagnosing Group A Streptococcus (GAS). It also had a 100% Negative Predictive Value (NPV), meaning it was highly reliable in confirming the absence of Streptococcus A infection.
• Easy to Use Anywhere – No special equipment is needed—just a smartphone. This makes it easy to expand globally, especially in areas with limited healthcare access.
• Fast Results – Delivers answers in under a minute, compared to the hours or even days required by traditional methods.

AI is a Powerful Assistant, NOT a Replacement to Human

Doctors use their experience, physical exams, and tests to diagnose medical conditions. Their training helps them catch subtle symptoms that AI might miss. Doctors and hospitals are using AI to not only help them save time and money – but to help save lives.

As AI continues to evolve, it will make healthcare more accessible and efficient. Doctors and hospitals are using AI to not only help them save time and money – but to help save lives.

But for now, your doctor’s expertise is still irreplaceable!

Companies like LightAI are only pushing the boundaries. Its AI symptom checker is convenient and highly accurate. While it still needs regulatory approval, it could be a game-changer in remote diagnosis. Nonetheless, the best approach is to use AI as a helpful tool for quick insights, but rely on doctors for a final diagnosis and treatment plan.

Disclaimer 

New Era Publishing Inc. (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Light AI Inc. made a one-time payment of $10,000 to provide marketing services for a term of 1 month through Barchart. We or certain non-arms length parties own common shares of Light AI Inc. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

Forward Looking Statements 

This article contains forward-looking statements about Light AI Inc., which are identified by terms such as "anticipate," "expect," and "project." These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article's publication date and we undertake no obligation to update.

The above is sponsored content. Barchart was paid up to ten thousand dollars for the placement and promotion of the content on this site and other forms of public distribution covering the period of March 2025.  For more information, please view the Barchart Disclosure Policy here.